Affinity-Based Controlled Release System for Therapeutic Proteins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current protein-based therapeutic delivery methods face challenges such as protein bioactivity loss during encapsulation and limited tunability of release rates, particularly in affinity-based systems which are often limited to specific proteins like heparin-binding proteins or require specific scaffolds.
Innovation Solution
A composition comprising a chimeric molecule with a biologically active molecule and a first binding moiety covalently linked to a polymer matrix with a second binding moiety, allowing reversible binding with a dissociation constant between 10−3 and 10−9, enabling extended and tunable release of therapeutic agents like recombinant human basic fibroblast growth factor (rhFGF2) or chondroitinase ABC.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If protein encapsulation is used to control protein release, then a diffusive barrier is provided, but protein bioactivity is diminished and drug loading is low
Solution Approach 1:
The patent introduces an affinity-based binding system as an intermediary mechanism between the polymer matrix and therapeutic protein. Instead of relying on encapsulation within particles, the system uses specific binding interactions (e.g., heparin-binding domains, collagen-binding domains, or engineered affinity tags) to sequester proteins at the matrix level, thereby maintaining bioactivity while achieving high loading capacity through reversible binding equilibrium.
Solution Approach 2:
The patent replaces the mechanical encapsulation approach (physical trapping within nano-/micro-particles) with a chemical/biochemical affinity-based system. This substitution eliminates the need for harsh encapsulation processes that compromise protein structure, while the reversible binding provides controlled release through dynamic equilibrium rather than diffusion barriers.
2Adaptability or versatility
If heparin or heparin-binding peptides are immobilized to deliver heparin-binding proteins, then release is controlled, but the system is limited to heparin-binding proteins only
Solution Approach 1:
The patent creates a universal affinity-based platform that can deliver multiple types of therapeutic proteins through different binding mechanisms. The system incorporates various binding domains (heparin-binding, collagen-binding, fibronectin-binding, or engineered affinity tags like GST or MBP) that can be matched to corresponding therapeutic proteins, making the system versatile across different protein targets while maintaining controlled release through affinity-based sequestration.
Solution Approach 2:
The patent controls release rates by adjusting affinity binding parameters such as the dissociation constant (Kd) of the binding interaction, the density of binding sites on the polymer matrix, and the concentration of therapeutic protein. By tuning these parameters, the system achieves controllable release for different protein types without being limited to a single protein class.
3Adaptability or versatility
If recombinant human basic fibroblast growth factor (rhFGF2) binding peptide is used to control release from PEG hydrogels, then release is controlled, but the system is limited to FGF2 only
Solution Approach 1:
The patent extends the affinity-based release mechanism beyond FGF2-specific binding to a universal platform that can deliver diverse therapeutic proteins. By incorporating multiple types of binding domains (heparin-binding, collagen-binding, fibronectin-binding, and engineered affinity tags) into the polymer matrix, the system maintains controlled release capability while becoming applicable to a broad range of therapeutic agents including growth factors, cytokines, and enzymes.
4Adaptability or versatility
If collagen scaffolds are used to bind therapeutic fusion proteins, then binding is achieved, but the rate of release cannot be tuned and collagen scaffold is required
Solution Approach 1:
The patent enables tunable release rates by modifying affinity binding parameters including the dissociation constant (Kd) of the binding interaction, the density and distribution of binding sites on the polymer matrix, and the concentration of therapeutic protein. This parameter-based control allows precise adjustment of release kinetics without requiring complex scaffold structures or multiple components.
Solution Approach 2:
The patent extracts the essential binding function from complex collagen scaffolds and implements it through simpler affinity-based interactions on polymer matrices. By removing the requirement for collagen scaffold structure while retaining the binding capability through engineered affinity domains or tags, the system achieves release control with reduced structural complexity and expanded material choices.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a versatile platform for extended and controlled release of therapeutic proteins, maintaining bioactivity and allowing for tunable release profiles, as demonstrated by sustained release of rhFGF2 and ChABC for several days, overcoming the limitations of existing methods.
Implementation Method 1
affinity-based release of therapeutic agents from a polymer wherein each of the therapeutic agent and polymer contain corresponding binding partners that through their reversible binding interaction control the release of the therapeutic agent from the polymer
Data Source
AI summary
Prolonged or extended release of bioactive protein is achieved using an affinity-based approach which exploits the specific binding of Src homology 3 (SH3) domain with short proline-rich peptides. Specifically, methylcellulose was modified with SH3-binding peptides (MC-peptide) with either a weak affinity or strong affinity for SH3. Controlled release of chondroitinase ABC (ChABC) is also described.